{"preliminary_commentary":{"by_channel":{"podcast":19,"x_thread":15,"youtube":14},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03165734\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pacritinib"]],"indication":"myelofibrosis with severe thrombocytopenia","name":"PACIFICA","nct_id":"NCT03165734","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacifica-nct03165734. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACIFICA","arms":[{"description":"To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food","label":"Pacritinib 200 mg BID","type":"EXPERIMENTAL"},{"description":"The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.","label":"Physician's Choice (P/C) therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["PSI CRO"],"completion_date":{"date":"2028-10-13","type":"ESTIMATED"},"conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":{"count":407,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pacritinib","otherNames":[],"type":"DRUG"},{"name":"Physician's Choice medications","otherNames":["corticosteroids","hydroxyurea","danazol","low-dose ruxolitinib"],"type":"DRUG"}],"last_update":"2026-04-30","lead_sponsor":"Swedish Orphan Biovitrum","official_title":"A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Spleen volume","timeFrame":"From baseline at 24 weeks"},{"measure":"Total Symptom Score (TSS) (excluding tiredness)","timeFrame":"From baseline at Week 24"}],"references":[{"citation":"Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, Yacoub A, Vannucchi A, Mead AJ, Kiladjian JJ, O'Sullivan J, Garcia-Gutierrez V, Bose P, Rampal RK, Miller CB, Palmer J, Oh ST, Buckley SA, Mould DR, Ito K, Tyavanagimatt S, Smith JA, Roman-Torres K, Devineni S, Craig AR, Mascarenhas JO. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24;4(22):5825-5835. doi: 10.1182/bloodadvances.2020003314.","pmid":"33232476","type":"DERIVED"}],"start_date":{"date":"2017-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","url":"https://clinicaltrials.gov/study/NCT03165734"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacifica-nct03165734"}